|
|
|
|
| LEADER |
04554nma a2201045 u 4500 |
| 001 |
EB002172512 |
| 003 |
EBX01000000000000001310289 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
230811 ||| eng |
| 020 |
|
|
|a 9783036579269
|
| 020 |
|
|
|a books978-3-0365-7926-9
|
| 020 |
|
|
|a 9783036579276
|
| 100 |
1 |
|
|a Paleari, Laura
|
| 245 |
0 |
0 |
|a Cancer Prevention with Molecular Target Therapies
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2023
|
| 300 |
|
|
|a 1 electronic resource (208 p.)
|
| 653 |
|
|
|a overall survival
|
| 653 |
|
|
|a multidrug resistance
|
| 653 |
|
|
|a ARF
|
| 653 |
|
|
|a β3-tubulin
|
| 653 |
|
|
|a ABC transporter
|
| 653 |
|
|
|a dysbiosis
|
| 653 |
|
|
|a GANT61
|
| 653 |
|
|
|a hepatocellular carcinoma
|
| 653 |
|
|
|a human thymidylate synthase peptidic-inhibitors
|
| 653 |
|
|
|a pH-sensitive PEGylated liposomes
|
| 653 |
|
|
|a Cyclin D1
|
| 653 |
|
|
|a microvesicles
|
| 653 |
|
|
|a non-small-cell lung cancer (NSCLC)
|
| 653 |
|
|
|a Oncology / bicssc
|
| 653 |
|
|
|a aromatase inhibitors
|
| 653 |
|
|
|a gut microbiota
|
| 653 |
|
|
|a tyrosine kinase inhibitor
|
| 653 |
|
|
|a steroid receptors
|
| 653 |
|
|
|a tumor suppressor
|
| 653 |
|
|
|a 5-fluorouracil
|
| 653 |
|
|
|a muscle invasive
|
| 653 |
|
|
|a early stage
|
| 653 |
|
|
|a drug-resistance
|
| 653 |
|
|
|a non-muscle invasive
|
| 653 |
|
|
|a endometrial cancer
|
| 653 |
|
|
|a bladder cancer
|
| 653 |
|
|
|a STAT3
|
| 653 |
|
|
|a SLC transporter
|
| 653 |
|
|
|a osimertinib
|
| 653 |
|
|
|a raltitrexed
|
| 653 |
|
|
|a lysosomal sequestration
|
| 653 |
|
|
|a molecular subtypes
|
| 653 |
|
|
|a tumor promoter
|
| 653 |
|
|
|a prognosis
|
| 653 |
|
|
|a cancer
|
| 653 |
|
|
|a metabolites
|
| 653 |
|
|
|a ALK
|
| 653 |
|
|
|a NAFLD
|
| 653 |
|
|
|a DMTF1
|
| 653 |
|
|
|a biomarker
|
| 653 |
|
|
|a extracellular vesicles
|
| 653 |
|
|
|a melanoma
|
| 653 |
|
|
|a p53
|
| 653 |
|
|
|a ovarian cancer
|
| 653 |
|
|
|a cancer cell migration
|
| 653 |
|
|
|a INK4a
|
| 653 |
|
|
|a YY1
|
| 653 |
|
|
|a non-canonical Hedgehog-GLI signaling
|
| 653 |
|
|
|a EGFR
|
| 653 |
|
|
|a classification
|
| 653 |
|
|
|a evolution
|
| 653 |
|
|
|a adenocarcinoma
|
| 653 |
|
|
|a lipid metabolism
|
| 653 |
|
|
|a immune checkpoint inhibitor (ICI)
|
| 653 |
|
|
|a progression free survival
|
| 653 |
|
|
|a microtubules
|
| 653 |
|
|
|a HCC
|
| 653 |
|
|
|a NSCLC
|
| 653 |
|
|
|a targeted therapy
|
| 653 |
|
|
|a Medicine and Nursing / bicssc
|
| 700 |
1 |
|
|a Paleari, Laura
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-0365-7926-9
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/101339
|z DOAB: description of the publication
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/7434
|7 0
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 576
|
| 082 |
0 |
|
|a 304
|
| 082 |
0 |
|
|a 140
|
| 082 |
0 |
|
|a 380
|
| 520 |
|
|
|a Personalized medicine plays an important role in cancer prevention. To date, it is clear that many cancers are molecularly distinct subtypes, and different therapeutic approaches would be required for each. Indeed, the identification of cancer susceptibility genes permits identifying patients "at risk" of developing neoplasia and supports modifying individual risk behaviors or the choice of preventive therapy. Additionally, the efficacy of various targeted therapies in different cancer subtypes suggests that treatment choices in the near future will be more and more centered on molecular signatures. Data from preclinical, clinical, and observational studies have revealed the ability to prevent cancer development for compounds with different indications than cancer. The concept of drug repurposing permits combinations that can target several critical pathways of a specific disease, decreasing the risk of resistance observed when using single-agent targeted therapy.This open-access Special Issue brings together original research and review articles on molecular oncology with attention to the early detection and prevention of cancer. It highlights new findings, methods, and technical advances in molecular cancer research. The main feature of this Special Issue is to provide an open-source sharing of significant works in the field of molecular oncology that can increase our understanding of cancer development, which may lead to the discovery of new molecular diagnostic technologies and targeted therapeutics.
|